ABOUT US

Home

ABOUT US

COMPANY INTRODUCTION
GENEOUANTUM HEALTHCARE
(SUZHOU) CO., LTD.
GeneQuantum, headquartered in China, is a global leader in the ADC field, distinguished for its advancement of enzymatic site-specific conjugation technologies. Our pioneering technologies, iLDC and iGDC, serve as the foundation of our comprehensive ADC drug development platform, spanning from the initial design to seamless commercial production.


The technology offered by GQ provides numerous advantages, such as exceptional product homogeneity, elevated process quality, and enhanced metabolic stability. Our continuous conjugation process seamlessly integrates with standard antibody production, ensuring the efficient creation of high-quality ADC drugs that rival the efficiency of antibody drugs.
GQ's integrated approach leads to a substantial reduction in commercial production costs for ADCs. GQ remains steadfast in its commitment to delivering vital technical support, expediting global ADC drug development. Our dedication to collaborative synergy underpins mutual growth and success across diverse domains of ADC development.
Our vision
Our vision is to enhance global affordability and expand worldwide access to innovative ADC therapies, fulfilling truly unmet medical needs
HISTORY
Aug 2013
Company incorporated in bioBay, Suzhou Industrial Park, China
Mar 2017
GeneQuantum completed RMB 40 million Yuan Series A financing
Aug 2013
Company incorporated in bioBay, Suzhou Industrial Park, China
Mar 2017
GeneQuantum completed RMB 40 million Yuan Series A financing

2013-2017

Aug 2013
Company incorporated in bioBay, Suzhou Industrial Park, China
Mar 2017
GeneQuantum completed RMB 40 million Yuan Series A financing
Aug 2013
Company incorporated in bioBay, Suzhou Industrial Park, China
Mar 2017
GeneQuantum completed RMB 40 million Yuan Series A financing

2018-2020

Sept 2019
GeneQuantum completed Pre-B round of financing
Dec 2019
GQ1001 Australian clinical trial approved
May 2020
GQ1001 US clinical trial approved
Jul 2020
GQ1001 completed dosing of first subject in Australia
Oct 2020
Completed Series B financing
Sept 2019
GeneQuantum completed Pre-B round of financing
Dec 2019
GQ1001 Australian clinical trial approved
May 2020
GQ1001 US clinical trial approved
Jul 2020
GQ1001 completed dosing of first subject in Australia
Oct 2020
Completed Series B financing

2021-2023

May 2021
GeneQuantum completed hundreds of millions of RMB Series C financing
Nov 2021
Awarded as the ‘Potential Unicorn’ in Jiangsu Province
Jan 2022
GeneQuantum Global R&D Headquarter opening
Apr 2022
GeneQuantum and Aimed sign Global Collaboration Agreement on First-in-class ADC Drugs
May 2022
GeneQuantum's Next Generation GQ1005 and First AIAC DrugGQ1007 are approved for Clinical Use in Australia
Sept 2022
U.S. Patent Approved for LDC Technology
Dec 2022
GQ1005 completed dosing of first subject
Dec 2022
GeneQuantum enters a Strategic collaboration with WuXi XDC
Apr 2023
GeneQuantum enters License Agreement with Pyramid
Apr 2023
GeneQuantum enters a strategic collaboration with Asymchem
June 2023
Awarded the ‘China Potential Unicorn’
May 2021
GeneQuantum completed hundreds of millions of RMB Series C financing
Nov 2021
Awarded as the ‘Potential Unicorn’ in Jiangsu Province
Jan 2022
GeneQuantum Global R&D Headquarter opening
Apr 2022
GeneQuantum and Aimed sign Global Collaboration Agreement on First-in-class ADC Drugs
May 2022
GeneQuantum's Next Generation GQ1005 and First AIAC DrugGQ1007 are approved for Clinical Use in Australia
Sept 2022
U.S. Patent Approved for LDC Technology
Dec 2022
GQ1005 completed dosing of first subject
Dec 2022
GeneQuantum enters a Strategic collaboration with WuXi XDC
Apr 2023
GeneQuantum enters License Agreement with Pyramid
Apr 2023
GeneQuantum enters a strategic collaboration with Asymchem
June 2023
Awarded the ‘China Potential Unicorn’
MANAGEMENT TEAM
Gang Qin, Ph.D, CEO
Gang Qin, Ph.D, CEO
Founder/Chairman
Paul H.Song, Ph.D., CSO
Paul H.Song, Ph.D., CSO
Innovation Drug R&D and Pipeline building
Yan shi, Ph.D., CMO
Yan shi, Ph.D., CMO
Leading China & global clinical drug development
Li Wan, Ph.D., CDO
Li Wan, Ph.D., CDO
Responsible for global regulatory affairs, project management, and alliance management
Amy Que, Ph.D., CTO
Amy Que, Ph.D., CTO
Responsible for CMC and Quality
Gang Qin, Ph.D, CEO
Founder/Chairman

Experience:

Post-Doc, Max-Planck Institute of Biochemistry

Project Leader of DFG, Max-Planck Institute of Biochemistry

Principal lnvestigator, Tianjin lnstitute of lndustrial Biotechnology, Chinese Academy of Sciences

Leading Science & Technology Entrepreneur Talents Nanjing 321

Leading Entrepreneur Talents Suzhou Industrial Park


Education:

Nankai University, BS Biochemistry/MS Molecular biology

Georg-August-Universität/Max-Planck lnstitute of Biophysical Chemistry, Goettingen, Germany, Ph.D Neurobiology


Paul H.Song, Ph.D., CSO
Innovation Drug R&D and Pipeline building

Responsibilities:

Establishing a world-class R&D structure specializing in bioconjugates, integrating innovative science and cutting-edge technologies.

Leading the development of next generation first/best-in-class bioconjugate drug pipelines that significantly advance the current treatment landscape.

Leading technology innovation at GQ, focusing on unique iLDC/iGDC conjugation technologies, stable linker technologies, and novel payload development.


Experience:

Chief Scientific Officer (CSO) at Curon Biopharmaceutical, China

Vice President (VP) at Samsung Bioepis, Korea

Principal Research Scientist at Eli Lilly Research Laboratories, USA

Post-Doctoral Researcher at Tularik Inc. (Amgen SF), USA


Education:

Ph.D. in Biology from Purdue University, USA


Yan shi, Ph.D., CMO
Leading China & global clinical drug development

Responsibilities:

Make the GQ’s clinical development strategy

Direct and oversee the design and implementation of all stage clinical projects

Prepare and direct overall clinical development plans

Design scientifically rigorous clinical development programs for the various indications

Monitor study progress, leading the analyses and data evaluation process for progress reporting and presentations to internal senior management team and external advisory and other relative groups

Prepare briefing and regulatory documents for regulatory agencies, such as BLAs, INDs, DSUR, and communicate with regulatory agencies about medical and other related issues

Planning and promotion of clinical professional activities


Experience:

Associate Chief Physician, Ruijin Hospital, Shanghai Jiaotong University School

Associate Chief Physician, associate professor, Chinese PLA General Hospital & Chinese PLA Medical School


Education:

Post-doctor, Dana-Farber Cancer Institute, USA

PhD., MD. in oncology, Chinese PLA General Hospital & Chinese PLA Medical School, China

MS, in pathology and pathophysiology, Chinese PLA General Hospital & Chinese PLA Medical School, China

BS, in Clinical medicine, Southern Medical University (The First Military Medical University of the PLA), China

Li Wan, Ph.D., CDO
Responsible for global regulatory affairs, project management, and alliance management

Responsibilities:

Lead global regulatory submissions and develop regulatory and clinical strategies for all GQ pipeline products

Lead all aspects of cross-functional project management for drug development programs from preclinical to commercialization

Manage strategic alliances and external collaboration to maximize asset value of partnered programs


Experience:

Senior Vice President, GeneQuantum Healthcare

Vice President, Alphamab Oncology

Vice President, Luye Pharma

Global Regulatory Project Lead, GRA, Novartis

Senior Research Scientist, Pfizer Global Research & Development


Education:

Ph.D. Pharmaceutics, Rutgers University, USA (Graduate Advisor: Dr. Patrick J. Sinko)

M.S,Department of Biology, Nanjing University, China

B.S,Department for Intensive Instruction, Nanjing University, China

Amy Que, Ph.D., CTO
Responsible for CMC and Quality

Responsibilities:

Responsible for establishing and optimizing GMP quality system

Responsible for CMC development and manufacturing to ensure the smooth progress of the projects


Experience:

Chief Technology Officer, Harbour BioMed, Suzhou/Shanghai , PR China

Senior VP,Innovent Biologics, Inc.. Suzhou, PR China


Education:

Ph.D., Bioanalytical Chemistry, Indiana University, Bloomington, IN